23
Views
27
CrossRef citations to date
0
Altmetric
Original Articles

Multidrug resistance-associated biomarkers PGP, GST-π, Topo-II and LRP as prognostic factors in primary ovarian carcinoma

, , , &
Pages 69-74 | Accepted 13 Dec 2010, Published online: 23 May 2016

References

  • Parker SL, Tong T, Bolden, Wingo PA. Cancer statistics. 1997. CA Cancer J Clin 1997; 47 (1): 5–27. Erratum in CA Cancer J Clin 1997; 47 (2): 68.
  • Guo P, Lu H, Chen YL et al. Clinical significance of multidrug resistance protein expression in non-small cell lung cancer. Sichuan J Cancer Control 2005; 18: 144–7.
  • Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329 (21): 1550–9. Erratum in N Engl J Med 1994; 330 (6): 448.
  • Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futagami M, Saito Y. Significance of multidrug-resistant protein in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 1999; 25 (6): 387–94.
  • Yin MB, Guo B, Voigt W et al. Novel cellular determination for reversal of multidrug resistance in cells expressing of p170-glycoprotein. Biochim Biophys Acta 1998; 1401 (3): 265–76.
  • Holzamayer TA, Hilsenbeck S, Hoff DD et al. Clinical Correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small cell lung carcinoma. J Natl Cancer Inst 1992; 84 (19): 1468–91.
  • Green JA, Roberton LJ, Clark AH. Glutathione S-transferase expression in benign and malignant ovarian tumours. Br J Cancer 1993; 68 (2): 235–9.
  • Vanhoefer H, Yin MB, Harstrick, Seeber S, Rustum YM. Carbamoylation of glutathione reductase by N,N-bis (2-chloroethyl)-N-nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Biochem Pharmacol 1997; 53 (6): 801–9.
  • Dang DT, Chen F, Kohli M, Rago C, Cummins JM, Dang LH. Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res 2005; 65 (20): 9485–94.
  • Duca M, Guianvarc’h D, Oussedik K et al. Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides. Nucleic Acids Res 2006; 34 (6): 1900–11.
  • Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C. Topotecan – a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 1999; 56 (1): 1–12.
  • Dalton WS, Scheper RJ. Lung resistance-related protein: determining its role in multidrug resistance. J Natl Cancer Inst 1999; 91 (19): 1604–5.
  • Arts HJ, Katsaros D, de Vries EG et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 1999; 5 (10): 2798–805.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.